Upul Wickramarachchi 🇱🇰🇬🇧 (@upulwick) 's Twitter Profile
Upul Wickramarachchi 🇱🇰🇬🇧

@upulwick

Interventional Cardiologist
DCB/DEB enthusiast

ID: 2196672456

calendar_today15-11-2013 21:53:40

449 Tweet

304 Followers

562 Following

MyJSCAI (@myjscai) 's Twitter Profile Photo

📖Game-changer in #ACS treatment. Introducing a novel stentless strategy: gradual, prolonged pre-dilation w perfusion balloon & drug-coated balloon. High success rates & minimal complications. #DCB #Stentless ➡️ doi.org/10.1016/j.jsca…

📖Game-changer in #ACS treatment. Introducing a novel stentless strategy: gradual, prolonged pre-dilation w perfusion balloon & drug-coated balloon. High success rates & minimal complications. #DCB #Stentless

➡️ doi.org/10.1016/j.jsca…
Vass Vassiliou (@vass_vassiliou) 's Twitter Profile Photo

17 days till ESC Preventive Cardiology in #Milan! Still time to join and enjoy an amazing conference! Register here: escardio.org/Congresses-Eve… And i need 17 followers to reach 10,000!!! Can you help me achieve that before the conference??!!! EAPCPresident Prof Michael Papadakis

17 days till ESC Preventive Cardiology in #Milan! Still time to join and enjoy an amazing conference! 

Register here: escardio.org/Congresses-Eve…

And i need 17 followers to reach 10,000!!! Can you help me achieve that before the conference??!!! 

<a href="/EAPCPresident/">EAPCPresident</a> <a href="/MichaelPapadak2/">Prof Michael Papadakis</a>
European Society of Cardiology Journals (@esc_journals) 's Twitter Profile Photo

A simplified definition of a statin-eligible primary prevention patient is one who is: • 40–70 years old w/ LDL-C ≥ 3.0 mmol/L or • 55–80 years old with LDL-C ≥ 1.8 mmol/L & additional risk factors 💊 ow.ly/K6vm50Vhffm EJHF Editor-in-Chief Jan Biegus #HFA_ESC #ESCHeartFailure

A simplified definition of a statin-eligible primary prevention patient is one who is: • 40–70 years old w/ LDL-C ≥ 3.0 mmol/L or • 55–80 years old with LDL-C ≥ 1.8 mmol/L &amp; additional risk factors 💊 ow.ly/K6vm50Vhffm

<a href="/EJHFEiC/">EJHF Editor-in-Chief</a> <a href="/JanBiegus/">Jan Biegus</a> #HFA_ESC #ESCHeartFailure
C. Michael Gibson MD (@cmichaelgibson) 's Twitter Profile Photo

Late-breaker at #ACC25: Dr. Matthew Budoff presented the EKSTROM trial, showing low-dose colchicine reduces total plaque volume at 1 year in stable CAD pts compared to placebo. Slides here: clinicaltrialresults.org/wp-content/upl…

Late-breaker at #ACC25: Dr. Matthew Budoff presented the EKSTROM trial, showing low-dose colchicine reduces total plaque volume at 1 year in stable CAD pts compared to placebo. Slides here: clinicaltrialresults.org/wp-content/upl…
Davide Capodanno (@dfcapodanno) 's Twitter Profile Photo

Our Commission, now published in The Lancet, advocates redefining coronary artery disease as atherosclerotic coronary artery disease (ACAD). This shift moves beyond the traditional ischemia-centered model to a systematic approach addressing atherosclerosis earlier. We believe

Our Commission, now published in The Lancet, advocates redefining coronary artery disease as atherosclerotic coronary artery disease (ACAD). This shift moves beyond the traditional ischemia-centered model to a systematic approach addressing atherosclerosis earlier. We believe
Saad Ur Rahman (@saadurrahman55) 's Twitter Profile Photo

Takeaways from #ACC2025. Late breaking trials - take home points American College of Cardiology   1. WARRIOR Trial : Intensive medical therapy did not significantly impact the rate of serious cardiovascular events at five years in women with suspected ischemia with nonobstructive coronary arteries

CircInterventions (@circintv) 's Twitter Profile Photo

Is one drug better than another? A randomized comparison of sirolimus-coated balloon versus paclitaxel-coated balloon for the treatment of in-stent restenosis #cardiotwitter #AHAJournals ahajrnls.org/3YhfqDV

Is one drug better than another? A randomized comparison of sirolimus-coated balloon versus paclitaxel-coated balloon for the treatment of in-stent restenosis #cardiotwitter #AHAJournals ahajrnls.org/3YhfqDV
European Society of Cardiology Journals (@esc_journals) 's Twitter Profile Photo

A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy individuals was predictive of incident MACE during a 20-year period. Read the results of the EPIC-Norfolk study in #EHJ 👉 ow.ly/MVQ950Vvjwu Rocco Montone EHJ Editor-in-Chief #prevention

A single combined measure of LDL cholesterol, hsCRP, and Lp(a) among initially healthy individuals was predictive of incident MACE during a 20-year period. Read the results of the EPIC-Norfolk study in #EHJ 👉 ow.ly/MVQ950Vvjwu

<a href="/RoccoMontone/">Rocco Montone</a> <a href="/ehj_ed/">EHJ Editor-in-Chief</a> #prevention
EuroIntervention (@eurointerventio) 's Twitter Profile Photo

🆕 AHEAD OF PRINT OUT TODAY ‼️ The Drug-Coated Balloon Academic Research Consortium provided standardized definitions and endpoints for DCB clinical research in CAD. This consensus aims to harmonize trial design, lesion assessment, and reporting across studies. 👉👉Open

🆕  AHEAD OF PRINT OUT TODAY ‼️ 
The Drug-Coated Balloon Academic Research Consortium provided standardized definitions and endpoints for DCB clinical research in CAD. This consensus aims to harmonize trial design, lesion assessment, and reporting across studies. 
👉👉Open
Indah Sukmawati, MD (@indahsp_md) 's Twitter Profile Photo

Some of my 🔑 Key Takeaways on Left Main Bifurcation PCI sessions from D1 and D2 of #TCTAP2025 and 📑 🔷️Stenting Strategy Should Be Personalized The DKCRUSH-V trial showed DK crush is superior to provisional stenting for true LM bifurcations. However, EBC-MAIN found no

Some of my 🔑 Key Takeaways on Left Main Bifurcation PCI sessions from D1 and D2 of #TCTAP2025 and 📑

🔷️Stenting Strategy Should Be Personalized
The DKCRUSH-V trial showed DK crush is superior to provisional stenting for true LM bifurcations. However, EBC-MAIN found no
European Society of Cardiology Journals (@esc_journals) 's Twitter Profile Photo

Long-term trials of colchicine for secondary prevention of vascular events. Discover the results of a meta-analysis just published in #EHJ 👉 ow.ly/uJgm50VNwLE Rocco Montone EHJ Editor-in-Chief #prevention #colchicine

Long-term trials of colchicine for secondary prevention of vascular events. Discover the results of a meta-analysis just published in #EHJ 👉 ow.ly/uJgm50VNwLE

<a href="/RoccoMontone/">Rocco Montone</a> <a href="/ehj_ed/">EHJ Editor-in-Chief</a> #prevention #colchicine
Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

GLP-1 receptor agonists: more than glycemic control and weight loss. They reduce inflammation, improve cardiovascular & kidney health, and may benefit neurodegenerative & psychiatric conditions. Clinical trials are unlocking their full potential. #GLP1 nature.com/articles/s4225…

GLP-1 receptor agonists: more than glycemic control and weight loss. They reduce inflammation, improve cardiovascular &amp; kidney health, and may benefit neurodegenerative &amp; psychiatric conditions. Clinical trials are unlocking their full potential. #GLP1
nature.com/articles/s4225…
American College of Cardiology (@accintouch) 's Twitter Profile Photo

Colchicine substantially reduces MACE including cardiovascular death, #cvMI and ischemic stroke compared with placebo in patients with vascular disease, according to two meta-analyses of randomized controlled trials. Read more: bit.ly/4djwMGP #cvPrev #CardioX

JACC Journals (@jaccjournals) 's Twitter Profile Photo

Chronic stent recoil occurred in 1 of 5 lesions treated with second- or newer-generation #DES requiring repeat #revasc, with severe calcium and nonuniform stent expansion identified as risk factors, and was associated with TLR. jacc.org/doi/10.1016/j.… #JACCINT #OCT

Chronic stent recoil occurred in 1 of 5 lesions treated with second- or newer-generation #DES requiring repeat #revasc, with severe calcium and nonuniform stent expansion identified as risk factors, and was associated with TLR. jacc.org/doi/10.1016/j.… #JACCINT #OCT
JACC Journals (@jaccjournals) 's Twitter Profile Photo

Stent-free #PCI? ✅ With lesion preparation, DCBs offer a safe & effective option in #cvCAD, reducing restenosis, stent thrombosis, & #DAPT needs. The new Asia-Pacific consensus supports DCB-first strategies in real-world care. jacc.org/doi/10.1016/j.… #JACCAsia #ACCIntl #DCB

Stent-free #PCI? ✅

With lesion preparation, DCBs offer a safe &amp; effective option in #cvCAD, reducing restenosis, stent thrombosis, &amp; #DAPT needs. The new Asia-Pacific consensus supports DCB-first strategies in real-world care. jacc.org/doi/10.1016/j.… #JACCAsia #ACCIntl #DCB
Upul Wickramarachchi 🇱🇰🇬🇧 (@upulwick) 's Twitter Profile Photo

Spreading the word on DCB/stentless coronary angioplasty Yashoda Hospitals Hitec city, Hyderabad at Advanced Course in Clinical Cardiology. Thank you for the great hospitality.

Spreading the word on DCB/stentless coronary angioplasty <a href="/YashodaHospital/">Yashoda Hospitals</a> Hitec city,  Hyderabad at Advanced Course in Clinical Cardiology. Thank you for the great hospitality.